<DOC>
	<DOCNO>NCT00590161</DOCNO>
	<brief_summary>One third population United States nonalcoholic fatty liver disease ( NAFLD ) . Nonalcoholic steatohepatitis ( NASH ) , progressive form NAFLD , lead cirrhosis.Currently , proven therapy patient NASH . The investigator core hypothesis therapy patient NASH pentoxifylline ( PTX ) one year result improvement biochemical parameter liver disease hepatic histology . The focus proposal effectiveness pentoxifylline ( PTX ) improve laboratory tissue parameter liver disease , parameter insulin-resistance , level cytokines patient NASH .</brief_summary>
	<brief_title>Pentoxifylline Patients With Nonalcoholic Steatohepatitis</brief_title>
	<detailed_description />
	<mesh_term>Fatty Liver</mesh_term>
	<mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
	<mesh_term>Pentoxifylline</mesh_term>
	<criteria>Male female patient age 18 70 year . Liver biopsy compatible NASH , include presence steatosis necroinflammatory activity liver biopsy do prior 6 month study enrollment Daily alcohol intake &lt; 30 g male &lt; 15 g female ; Appropriate exclusion liver disease . Patients diabetes mellitus type 2 diagnosis define previous diagnosis DM current therapy antidiabetic agent , fulfillment 1997 American Diabetic Association ( ADA ) criterion , may include fulfill follow criterion : ( ) therapeutic regimen limit specific oral agent include sulfonylurea ( e.g . glipizide glyburide ) and/or biguanides ( e.g . metformin ) ; ( ii ) stable therapeutic regimen define change oral agent least 3 month ; ( iii ) Hemoglobin A1C ( HgbA1C ) &lt; 8.5 % . History past excessive alcohol drinking ( define ) period longer 2 year time past 10 year . Current consumption alcohol &gt; 30 g daily male &gt; 15 g daily female . Positive test hepatitis B surface antigen , hepatitis C virus antibody , ribonucleic acid ( RNA ) hepatitis C virus deoxyribonucleic acid ( DNA ) hepatitis B virus . Patients take medication know cause steatosis . Other cause liver disease suspect history , family interview , laboratory testing . Patients cirrhosis define stage 4 fibrosis liver biopsy , patient show unequivocal clinical evidence portal hypertension , thrombocytopenia , splenomegaly , esophageal varix . Patients take medication possible benefit NASH within 3 month prior liver biopsy . These medication include Vitamin E , Betaine , Sadenosylmethionine ( SAMe ) , thiazolidinediones , acarbose . Patients diabetes mellitus Insulin therapy . Patients diabetes mellitus therapy thiazolidinediones alphaglucosidase inhibitor acarbose Hypersensitivity pentoxifylline methylxanthines ( caffeine , theophylline , theobromine ) . History cerebral retinal hemorrhage . Other medical comorbidities ( cardiac , central nervous system , renal , cancer ) would interfere completion study . Patients take Theophylline Coumadin potential drugdrug interaction Pentoxifylline . Pregnant nursing woman .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>Fatty Liver</keyword>
	<keyword>Nonalcoholic fatty liver disease ( NALFD )</keyword>
	<keyword>NAFLD</keyword>
	<keyword>Nonalcoholic steatohepatitis ( NASH )</keyword>
	<keyword>NASH</keyword>
	<keyword>pentoxifylline</keyword>
</DOC>